UBS raised the firm’s price target on Cencora (COR) to $415 from $380 and keeps a Buy rating on the shares. The initial guidance for the U.S. Healthcare Solutions segment EBIT is doable, if not conservative, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora’s Strong Growth Potential and Market Position Justify Buy Rating and Increased Price Target
- Cencora price target raised to $400 from $340 at Evercore ISI
- Cencora price target raised to $395 from $355 at Baird
- Cencora price target raised to $380 from $340 at Mizuho
- Cencora, Inc. Reports Strong Fiscal 2025 Results